Published in Medical Letter on the CDC and FDA, August 28th, 2005
"This is an exciting milestone for Neurocrine and represents the company's first completed NDA filing," said Gary A. Lyons, president and CEO of Neurocrine Biosciences. "Data from these two submissions is supported by one of the most comprehensive clinical trial programs in insomnia and demonstrates the long-term safety and efficacy profile of indiplon in helping patients with sleep onset and sleep maintenance...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA